Urology Journal

ISSN: 1735-1308

Instant 2023
Vol. 20 (2023)

Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

Urology Journal, Vol. 20 (2023), , Page 7468
https://doi.org/10.22037/uj.v20i.7468

Abstract

Purpose – Implementation of multiparametric magnetic resonance imaging (mpMRI)  for prostate adenocarcinoma’s variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma.


Methods – Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of preoperative mpMRI images.


Results – Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400.


Conclusion – Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values.

Keywords:
  • prostate adenocarcinoma
  • prostate cancer variants
  • mpMRI
  • apparent diffusion coefficient.

How to Cite

Köseoğlu, H., Çevik Cenkeri, H., Eroğlu, T., & Yalçın, B. (2023). Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma. Urology Journal, 20, 7468. https://doi.org/10.22037/uj.v20i.7468

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209-49.

Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994; 152:2031-6.

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al; European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22:746-57.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019; 76:340-51.

Ueno Y, Takahashi S, Ohno Y, Kitajima K, Yui M, Kassai Y, et al. Computed diffusion-weighted MRI for prostate cancer detection: the influence of the combinations of b-values. Br J Radiol. 2015; 88:20140738.

Syer TJ, Godley KC, Cameron D, Malcolm PN. The diagnostic accuracy of high b-value diffusion- and T2-weighted imaging for the detection of prostate cancer: a meta-analysis. Abdom Radiol (NY). 2018; 43:1787-97.

Humphrey PA. Histopathology of Prostate Cancer. Cold Spring Harb Perspect Med. 2017 ;7:a030411.

Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R. Rare and Unusual Histological Variants of Prostatic Carcinoma: Clinical Significance. BJU Int. 2008; 102:1369-74.

Zelic R, Giunchi F, Fridfeldt J, Carlsson J, Davidsson S, Lianas L, et al. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clin Epidemiol. 2022 18; 14:59-70.

Rosenkrantz AB, Hindman N, Lim RP, Das K, Babb JS, Mussi TC,et al. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging. 2013; 38:694-700.

Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, Obara M,et al. Ultra-high b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging. 2013; 38:154-60.

Watts K, Li J, Magi-Galluzzi C, Zhou M. Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology. 2013; 63:574-9.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70:106-19.

Humphrey PA. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol. 2018;31: S64-70.

Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol. 2017; 72:492-5.

Currin S, Flood TA, Krishna S, Ansari A, McInnes MDF, Schieda N. Intraductal Carcinoma of the Prostate (IDC-P) Lowers Apparent Diffusion Coefficient (ADC) Values among Intermediate Risk Prostate Cancers. J Magn Reson Imaging. 2019; 50:279-87.

  • Abstract Viewed: 0 times
  • Just Accepted-7468 Downloaded: 0 times

Download Statastics

In case of persistent problems in registration, primary uploading of a submission or uploading of a revision, please send us the submission files on the journal email at:

urologyjournal@sbmu.ac.ir

and please attach the screenshot of the error or problem you encountered in uploading.

 

Make a Submission
Information
Keywords